Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).

Costa, Rogério A

Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). [electronic resource] - Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie Sep 2007 - 1273-80 p. digital

Publication Type: Clinical Trial; Journal Article

0721-832X

10.1007/s00417-007-0557-x doi


Aged
Aged, 80 and over
Angiogenesis Inhibitors--adverse effects
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Humanized
Bevacizumab
Choroidal Neovascularization--diagnosis
Drug Therapy, Combination
Feasibility Studies
Female
Fluorescein Angiography
Humans
Injections
Macular Degeneration--complications
Male
Photochemotherapy
Photosensitizing Agents--adverse effects
Porphyrins--adverse effects
Prospective Studies
Vascular Endothelial Growth Factor A--antagonists & inhibitors
Verteporfin
Visual Acuity
Vitreous Body